{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:15:44Z","timestamp":1760148944445,"version":"build-2065373602"},"reference-count":98,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RC-2022-2773354"],"award-info":[{"award-number":["RC-2022-2773354"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondazione Donato-Venturi","award":["RC-2022-2773354"],"award-info":[{"award-number":["RC-2022-2773354"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1\/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.<\/jats:p>","DOI":"10.3390\/ijms241310415","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T01:35:11Z","timestamp":1687311311000},"page":"10415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improvements in Systemic Therapies for Advanced Malignant Mesothelioma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-5049","authenticated-orcid":false,"given":"Chiara","family":"Deiana","sequence":"first","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tavolari","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-2765","authenticated-orcid":false,"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajim.22955","article-title":"North-south gradient of mesothelioma and asbestos consumption-production in the United States-Progresses since the 1st asbestos partial ban in Am","volume":"62","author":"Sun","year":"2019","journal-title":"J. Ind. Med."},{"key":"ref_2","unstructured":"CDC (2023, April 14). Incidence of Malignant Mesothelioma, 1999\u20132018, Available online: https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no27-incidence-malignant-mesothelioma-1999-2018.htm."},{"key":"ref_3","unstructured":"(2023, April 14). Survival Rates for Malignant Mesothelioma. Available online: https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/detection-diagnosis-staging\/survival-statistics.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase iii study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Gaafar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1200\/JCO.2016.34.15_suppl.8554","article-title":"Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis","volume":"34","author":"Srour","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemona\u00efve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","first-page":"553","article-title":"Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB Clin","volume":"21","author":"Dudek","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): An investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"Stigt","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","unstructured":"PrECOG, LLC. (2023, March 30). DREAM3R: DuRvalumab (MEDI4736) with ChEmotherapy as First Line TreAtment in Advanced Pleural Mesothelioma\u2014A Phase 3 Randomised Trial, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334759."},{"key":"ref_14","unstructured":"Canadian Cancer Trials Group (2023, March 30). A Phase II\/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02784171."},{"key":"ref_15","unstructured":"ETOP IBCSG Partners Foundation (2023, March 30). A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy versus Bevacizumab and Standard Chemotherapy as First-Line Treatment for Advanced Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2015","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_20","unstructured":"Berneman, Z. (2023, January 19). First-Line Immunotherapy Using Wilms\u2019 Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02649829."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e000251","DOI":"10.1136\/jitc-2019-000251","article-title":"T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma","volume":"8","author":"Vroman","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma","volume":"181","author":"Veltman","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","unstructured":"Amphera, B.V. (2023, January 19). A Randomized, Open-Label Phase II\/III Study with Dendritic Cells Loaded with Allogeneic Tumour Cell Lysate (PheraLys) in Subjects with Mesothelioma as Maintenance Treatment (MesoPher) after Chemotherapy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03610360."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation with Pegylated Arginine Deiminase in Patients with Argininosuccinate Synthetase 1\u2013Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients with Argininosuccinate Synthetase 1\u2013Deficient Thoracic Cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_29","unstructured":"Polaris Group (2023, March 30). Randomized, Double-Blind, Phase 2\/3 Study in Subjects with Malignant Pleural Mesotheliomato Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2\/3 Study), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02709512."},{"key":"ref_30","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10637-008-9160-1","article-title":"A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer","volume":"27","author":"Kindler","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_32","unstructured":"Mirati Therapeutics Inc (2023, March 30). A Phase 1\/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with MTAP Homozygous Deletion, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05245500."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/358169a0","article-title":"Hsp90 chaperones protein folding in vitro","volume":"358","author":"Wiech","year":"1992","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1158\/1078-0432.CCR-20-1306","article-title":"Ganetespib in Combination with Pemetrexed\u2013Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial","volume":"26","author":"Fennell","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Zimmerman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21037\/tlcr-19-686","article-title":"Nivolumab in pre-treated malignant pleural mesothelioma: Real-world data from the Dutch expanded access program","volume":"9","author":"Cantini","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study","volume":"3","author":"Morra","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients with Advanced Unresectable Mesothelioma","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study","volume":"6","author":"Morra","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial","volume":"48","author":"Fennell","year":"2022","journal-title":"Eclinicalmedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and Gemcitabine as Second- or Third-Line Therapy for Malignant Pleural Mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III Trial of Pemetrexed Plus Best Supportive Care Compared with Best Supportive Care in Previously Treated Patients with Advanced Malignant Pleural Mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Toyokawa","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6673-3-34","article-title":"Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: An observational study","volume":"3","author":"Xanthopoulos","year":"2008","journal-title":"J. Occup. Med. Toxicol."},{"key":"ref_54","unstructured":"Curis, Inc (2023, January 12). A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02812875."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e004235","DOI":"10.1136\/jitc-2021-004235","article-title":"First-in-human phase I\/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors","volume":"10","author":"Davis","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_56","unstructured":"Incyte Biosciences International S\u00e0rl (2023, January 12). A Phase 1\/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03241173."},{"key":"ref_57","unstructured":"Incyte Biosciences International S\u00e0rl (2023, January 12). A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants with Select Advanced Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03538028."},{"key":"ref_58","unstructured":"Incyte Corporation (2023, January 12). A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants with Select Advanced Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03652077."},{"key":"ref_59","unstructured":"University of Pennsylvania (2023, January 18). A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Beta (BG00001, Ad.HIFN-\u03b2 for Pleural Malignancies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00299962."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-\u03b2 Gene Transfer for Mesothelioma and Metastatic Pleural Effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A Phase I Clinical Trial of Single-Dose Intrapleural IFN-\u03b2 Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-ifn\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_63","unstructured":"Trizell Ltd (2023, January 18). A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (RAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03710876."},{"key":"ref_64","first-page":"A1","article-title":"361 A randomised open-label phase I\/II study adding ONCOS-102 to pemetrexed\/cisplatin in patients with unresectable malignant pleural mesothelioma\u201412 month analysis of biomarkers and clinical outcomes","volume":"8","author":"Jaderberg","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_65","unstructured":"Memorial Sloan Kettering Cancer Center (2023, January 18). Combining a WT1 Cancer Vaccine (Galinpepimut-S) with Checkpoint Inhibition (Nivolumab) in Patients with WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04040231."},{"key":"ref_66","unstructured":"Momotaro-Gene Inc. (2023, March 16). A Phase 2, Open-Label, Single-Center Study of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04013334."},{"key":"ref_67","unstructured":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (2023, January 19). Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03546426."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_69","unstructured":"MD AZD (2023, January 19). Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03502746."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13046-022-02423-0","article-title":"Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers","volume":"41","author":"Baldini","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of Mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_76","unstructured":"Morphotek (2023, March 30). A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02357147."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"TPS8576","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8576","article-title":"A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum\/pemetrexed-based chemotherapy (NCT02610140)","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_79","unstructured":"National Cancer Institute (NCI) (2023, March 30). Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03126630."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted car t-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013pd-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies","volume":"13","author":"Kiesgen","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_86","unstructured":"University of Pennsylvania (2023, March 30). Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients with Progressive Malignant Pleural Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01355965."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients with Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-019-1265-1","article-title":"The roles of nuclear focal adhesion kinase (FAK) on Cancer: A focused review","volume":"38","author":"Zhou","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_90","unstructured":"NHS Greater Glasgow and Clyde (2023, March 16). A Phase I\/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies (FAK-PD1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02758587."},{"key":"ref_91","unstructured":"Verastem, Inc (2023, March 16). A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K\/MTOR Inhibitor, Administered with a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects with Relapsed Malignant Mesothelioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02372227."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients with Merlin-Stratified Pleural Mesothelioma: COMMAND\u2014A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_93","unstructured":"Ascentage Pharma Group Inc (2023, March 16). A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03917043."},{"key":"ref_94","unstructured":"GlaxoSmithKline (2023, March 16). A Phase 1b, Multi-Center, Open-Label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination with Trametinib (MEK Inhibitor) in Subjects with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01938443."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.jtho.2018.08.1264","article-title":"P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma","volume":"13","author":"Krebs","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:57:38Z","timestamp":1760126258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":98,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310415"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310415","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}